dovepress.com
Cure8 news brief
Why This Matters
Early prediction of who will not respond to infliximab could help clinicians avoid prolonged ineffective treatment, enabling earlier reassessment and changes in therapy as part of treat-to-target care.
Who Should Pay Attention
Adults with Crohn's disease starting infliximab, clinicians managing biologic induction, researchers studying treatment response prediction and biomarker-based models.
Study Snapshot
Story typeResearch paper
Evidence typeClinical study
Source depthFull source text
What To Know
This is a two-center, retrospective real-world cohort study of adults with Crohn’s disease starting infliximab as their first biologic (derivation cohort and an external validation cohort).
The investigators combined clinical non-response, objective inflammatory evidence (CRP, fecal calprotectin, endoscopy, imaging), and treatment-failure events to define PNR at ~Week 14, and they developed a parsimonious risk model using baseline and Week 2 indicators.
The model aims chiefly to identify patients at lower risk of PNR to support earlier, risk-informed clinical reassessment rather than to dictate immediate treatment changes.
The analysis used consecutively treated patients from two university hospitals, prespecified model selection and internal bootstrap validation in the derivation center, and independent external validation in the second center.
Because the work is retrospective, some data types (endoscopy, fecal biomarkers, drug levels) were variably available in routine practice, which the authors note as a limitation.
Keep In Mind
This is a retrospective real-world study with variable availability of endoscopy, fecal biomarkers, and therapeutic drug monitoring; findings are promising for risk stratification but require prospective validation before changing practice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationdovepress.com
Indexed viaGoogle News
Source typeWeb article
PublishedSep 22, 2026, 7:31 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Dose escalation for secondary loss of response in inflammatory bowel disease: 3-year outcomes and treatment persistence.
People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...
Circulating microRNAs as biomarkers of disease activity and treatment response in Crohn’s disease patients receiving infliximab or vedolizumab: a longitudinal cohort study
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.